Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : HMNC Brain Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KET01 is an oral prolonged-release ketamine formulation, a rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia typically in combination with a muscle relaxant. It is being currently developed for treatment-resist...
Product Name : Ketabon
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 28, 2023
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : HMNC Brain Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
